AVR-RD-02

N/A

Report date: 2023/08/24 20:01:02

Base Information

Drug NameAVR-RD-02

Drug Alias NameAVR-RD-02

ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapyCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vector

Mechanisms of ActionGene transferenceGlucosylceramidase replacements

TargetsBeta-glucocerebrosidaseGlucosylceramide

Therapy Area/IndicationsGaucher's disease type IIIGaucher Disease

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCanadaUnited States

CombinationsNo

Global Highest StatusDiscontinued (Phase 3 Clinical)

Highest Status in ChinaN/A

Originator CompaniesLund University Foundation

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesAvrobio

Active IndicationsN/A

Inactive IndicationsGaucher's disease type IIIGaucher Disease

Other Information

ATC CodeN/A